LCTX vs VRTX
LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | LCTX | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.11 | $472.57 | |
| Market cap as of 2026-07-23 | $278M | $121.4B | |
| P/E as of 2026-07-23 | n/a | 27.98 | |
| PEG as of 2026-07-23 | -0.02 | 2.31 | LCTX lower |
| Net margin as of 2026-07-23 | -431.2% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-23 | +94.1% | +86.2% | LCTX higher |
| Operating margin as of 2026-07-23 | -256.5% | +38.3% | VRTX higher |
| ROE as of 2026-07-23 | -151.3% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | -63.3% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | LCTX lower |
| Revenue growth (YoY) as of 2026-07-23 | -37.1% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +10.4% | VRTX higher |
| Beta as of 2026-07-23 | 1.51 | 0.30 | |
| 1-year return as of 2026-07-22 close | +16.8% | +0.5% | LCTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.